dc.contributor.author | Lavie, David | |
dc.contributor.author | Timmerman, John | |
dc.contributor.author | Sanz, Ramon Garcia | |
dc.contributor.author | Kim, Won Seog | |
dc.contributor.author | Kim, Tae Min | |
dc.contributor.author | Avigdor, Abraham | |
dc.contributor.author | Dierickx, Daan | |
dc.contributor.author | Jagadeesh, Deepa | |
dc.contributor.author | Herrera, Alex Francisco | |
dc.date.accessioned | 2024-01-25T12:04:07Z | |
dc.date.available | 2024-01-25T12:04:07Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Lavie, D., Timmerman, J., Sanz, R. G., Kim, W.S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023. | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12203 | |
dc.description.abstract | ... | en_US |
dc.description.sponsorship | Merck Sharp Dohme LLC | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hodgkin Lymphoma | en_US |
dc.subject | Refractory | en_US |
dc.subject | Chemotherapy | en_US |
dc.title | KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 41 | en_US |
dc.identifier.issue | 16 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001053772005450 | en_US |